BMY241115P58000
- 0.10
- -0.13-56.52%
Bristol-Myers Squibb Newsroom
Wolfe Research Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
Daiwa Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $65
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $60 to $73
Bristol-Myers Squibb Analyst Ratings
Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating
Leerink Partners Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $73
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $55 From $48
Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $36 From $37, Keeps Underweight Rating
Bristol-Myers Squibb Analyst Ratings
Citi Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Cuts Target Price to $55
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $53
Bristol-Myers Squibb: Navigating Financial Adjustments and Competitive Pressures Amidst a Hold Rating